PT  - JOURNAL ARTICLE
AU  - Tania M Welzel
AU  - David R Nelson
AU  - Giuseppe Morelli
AU  - Adrian Di Bisceglie
AU  - Rajender K Reddy
AU  - Alexander Kuo
AU  - Joseph K Lim
AU  - Jama Darling
AU  - Paul Pockros
AU  - Joseph S Galati
AU  - Lynn M Frazier
AU  - Saleh Alqahtani
AU  - Mark S Sulkowski
AU  - Monika Vainorius
AU  - Lucy Akushevich
AU  - Michael W Fried
AU  - Stefan Zeuzem
ED  - ,
TI  - Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study
AID  - 10.1136/gutjnl-2016-311609
DP  - 2017 Oct 01
TA  - Gut
PG  - 1844--1852
VI  - 66
IP  - 10
4099  - http://gut.bmj.com/content/66/10/1844.short
4100  - http://gut.bmj.com/content/66/10/1844.full
SO  - Gut2017 Oct 01; 66
AB  - Objective Due to a high efficacy in clinical trials, sofosbuvir (SOF) and ribavirin (RBV) for 12 or 16 weeks is recommended for treatment of patients with HCV genotype (GT) 2 infection. We investigated safety and effectiveness of these regimens for GT2 in HCV-TARGET participants.Design HCV-TARGET, an international, prospective observational study evaluates clinical practice data on novel antiviral therapies at 44 academic and 17 community medical centres in North America and Europe. Clinical data were centrally abstracted from medical records. Selection of treatment regimen and duration was the investigator's choice. The primary efficacy outcome was sustained virological response 12 weeks after therapy (SVR12).Results Between December 2013 and April 2015, 321 patients completed 12 weeks (n=283) or 16 weeks (n=38) of treatment with SOF and RBV. Prior treatment experience and cirrhosis was more frequent among patients in the 16-week regimen compared with 12 weeks (52.6% vs 27.6% and 63.2% vs 21.9%, respectively). Overall, SVR12 was 88.2%. The SVR12 in patients without cirrhosis was 91.0% and 92.9% for 12 or 16 weeks of therapy, respectively. In patients with cirrhosis treated for 12 or 16 weeks, SVR12 was 79.0% and 83%. In the multivariate analysis, liver cirrhosis, lower serum albumin and RBV dose at baseline were significantly associated with SVR12. Common adverse events (AEs) included fatigue, anaemia, nausea, headache, insomnia, rash and flu-like symptoms. Discontinuation due to AEs occurred in 2.8%.Conclusions In this clinical practice setting, SOF and RBV was safe and effective for treatment of patients with HCV GT2 infection.Trial registration number NCT01474811.